Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

but this miss means little to Novo Nordisk's long-term prospects. Further, the company has several exciting candidates in other areas, including rare diseases and neurological conditions such as ...

First Hawaiian Bank boosted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 30.3% in the fourth ...

International Assets Investment Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 98 ...

Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics ...

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

Novo Nordisk has started building its first ... metres, and will be used to make the company's rare disease therapies, such as its range of haemophilia drugs. Construction at the site has already ...